Askel Healthcare is a Finnish medical technology company dedicated to revolutionizing surgical knee cartilage treatment and recovery. Our mission is to keep people in motion with our groundbreaking COPLA® implant, a universal solution for repairing knee cartilage defects. The implant, which is the result of over a decade of orthopedic and tissue engineering research at the University of Helsinki and Tampere University, is easy to implant and enables a swift recovery to pain-free activity.

Our team of experts, including notable orthopedic surgeon and professor Ilkka Kiviranta, is committed to providing a global standard of surgical knee cartilage repair. With our founders' extensive backgrounds in orthopedic research, a high-caliber global collaboration network, and a competent team, we are at the forefront of cartilage repair. Currently in the clinical phase, Askel Healthcare's short-term strategic focus is on obtaining EU and US market authorizations by strengthening the clinical evidence of the COPLA® implant.

Our main goal is to launch and commercialize the implant in the EU and the US by 2028. At Askel Healthcare, we recognize that joint pain and loss of function significantly impact quality of life. Our aim is to empower individuals to regain control of their lives and enjoy the activities they love through our innovative solutions